Drug Profile
Heparin/lidocaine/sodium bicarbonate - Urigen Pharmaceuticals
Alternative Names: Alkalised lidocaine and heparin formulation - Urigen Pharmaceuticals; Hep-Lido-A compounded formulation; U 101; URG-101Latest Information Update: 14 Jan 2019
Price :
$50
*
At a glance
- Originator Urigen Pharmaceuticals
- Class Acetanilides; Alkalinising agents; Heparins; Local anaesthetics; Small molecules; Urologics
- Mechanism of Action Factor Xa inhibitors; Sodium channel antagonists; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Interstitial cystitis
- Discontinued Cystitis; Dyspareunia
Most Recent Events
- 31 Dec 2018 Imprimis Pharmaceuticals changed its name to Harrow Health and added all ophthalmology business to its subsidiary ImprimisRx
- 18 Jun 2018 Urigen terminates a phase II trial for Interstitial Cystitis in USA, based on interim study analysis (NCT02591199)
- 18 May 2015 Efficacy and pharmacokinetics data from a clinical trial in Interstitial cystitis released by Imprimis Pharmaceuticals